Short answer
Bio-Techne (TECH) filed its fiscal 2025 10-K annual report with the SEC on Aug 22, 2025. It reported revenue of $1.2B (+5.2% year over year) and net income of $73M.
- Top risk flagged: Cybersecurity risk due to potential breaches despite industry-standard defenses, reliance on third-party software and service providers increasing vulnerability
FY2025 key financial metrics · XBRL
- Revenue
- $1.2B
- +5.2% YoY
- Net income
- $73M
- −56.4% YoY
- Operating margin
- 8.4%
- −9.4 pp YoY
- Gross margin
- 64.8%
- −1.6 pp YoY
- EPS (diluted)
- $0.46
- −56.2% YoY
- ROE
- 3.8%
- −4.3 pp YoY
- Operating cash flow
- $288M
- −3.8% YoY
Source: XBRL data from the Bio-Techne (TECH) FY2025 10-K on SEC EDGAR. USD.
Bio-Techne FY2025 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model: Life sciences reagents, instruments, and services for research and clinical diagnostics
- No new products, services, or segments introduced or emphasized this year according to filing text
- No reported strategic shift or changed competitive positioning vs prior year
- Filing emphasizes extensive incorporation by reference to prior filings for governance, compensation, and legal matters, maintaining existing corporate structures
- Noteworthy: Filing contains no standalone 'Business' description content; relies entirely on cross-references and exhibits
Management Discussion & Analysis
- Revenue $1.22B in FY2025, up 5% YoY; Protein Sciences sales $870.2M (+5%), Diagnostics and Spatial Biology $346.3M (+6%)
- Gross margin declined to 64.8% in FY2025 vs 66.4% in FY2024; Protein Sciences margin 75.6% vs 75.7%, Diagnostics 57.3% vs 58.7%
- Best performing segment Diagnostics and Spatial Biology with 6% sales growth; worst Protein Sciences with 5% sales growth but margin pressure
- Operating expenses rose 26% to $588.5M in FY2025; net earnings down 56% to $98.5M driven by non-recurring arbitration loss and impairments
- Operating cash flow $287.6M in FY2025; capital expenditures $31M; share repurchases $275.7M; dividends $50.4M
- Management expects to meet cash needs through operations and credit facility; plans $42M capex in FY2026; risk from arbitration costs and Wilson Wolf acquisition milestone contingent payments (~$1B forecasted)
Risk Factors
- Cybersecurity risk due to potential breaches despite industry-standard defenses, reliance on third-party software and service providers increasing vulnerability
- Cyber insurance coverage may be insufficient to cover claims arising from security breaches or cyberattacks
- No specific regulatory, geopolitical, supply chain, competitive, or financial risks detailed in provided text
Generated from the filing text; verify against the original. How to read a 10-K
Other Bio-Techne annual reports
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.